florbetaben (18F)

This medicine is authorised for use in the European Union.


This is a summary of the European public assessment report (EPAR) for Neuraceq. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Neuraceq.

For practical information about using Neuraceq, patients should read the package leaflet or contact their doctor or pharmacist.

This EPAR was last updated on 18/07/2019

Authorisation details

Product details
Agency product number
Active substance
florbetaben (18F)
International non-proprietary name (INN) or common name
florbetaben (18F)
Therapeutic area (MeSH)
  • Radionuclide Imaging
  • Alzheimer Disease
Anatomical therapeutic chemical (ATC) code
Publication details
Marketing-authorisation holder
Life Radiopharma Berlin GmbH
Date of issue of marketing authorisation valid throughout the European Union
Contact address
Max-Planck-Straße 4
D-12489 Berlin

Product information

19/02/2019 Neuraceq - EMEA/H/C/002553 - IB/0027/G


Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

Diagnostic radiopharmaceuticals

Therapeutic indication

This medicinal product is for diagnostic use only.

Neuraceq is a radiopharmaceutical indicated for Positron Emission Tomography (PET) imaging of β amyloid neuritic plaque density in the brains of adult patients with cognitive impairment who are being evaluated for Alzheimer’s disease (AD) and other causes of cognitive impairment. Neuraceq should be used in conjunction with a clinical evaluation.

A negative scan indicates sparse or no plaques, which is not consistent with a diagnosis of AD.

Assessment history

How useful was this page?

Add your rating